Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James L Palmer

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Medical Economics|July 28, 2012
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysisWon Chan Lee, Yevgeniy Samyshkin, Jakob Langer, et al.
Journal of Medical Economics|March 31, 2010
Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US settingJames L Palmer, Martin S Knudsen, Mark Aagren, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 20, 2014
Validation of the IMS CORE Diabetes ModelPhil McEwan, Volker Foos, James L Palmer, et al.
Advances in Therapy|November 10, 2010
Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in ChinaJames L Palmer, Amélie Beaudet, Jeremy White, et al.
Journal of Medical Economics|April 9, 2015
Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in NorwayPernilla Huetson, James L Palmer, Andrée Levorsen, et al.
Journal of Medical Economics|May 14, 2011
Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UKAmélie Beaudet, James L Palmer, Louise Timlin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 1, 2010
Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South KoreaKyoung Hee Lee, Se Jin Seo, Jayne Smith-Palmer, et al.
Journal of Medical Economics|January 29, 2015
Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United StatesVolker Foos, Nebibe Varol, Bradley H Curtis, et al.
Current Medical Research and Opinion|April 11, 2008
Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE studyJames L Palmer, Gordon Goodall, Steffen Nielsen, et al.
Journal of Medical Economics|May 20, 2009
Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi ArabiaMohammed Ali, Jeremy White, Chen-Hui Lee, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Medical Economics|July 28, 2012
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysisWon Chan Lee, Yevgeniy Samyshkin, Jakob Langer, et al.
Journal of Medical Economics|March 31, 2010
Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US settingJames L Palmer, Martin S Knudsen, Mark Aagren, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 20, 2014
Validation of the IMS CORE Diabetes ModelPhil McEwan, Volker Foos, James L Palmer, et al.
Advances in Therapy|November 10, 2010
Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in ChinaJames L Palmer, Amélie Beaudet, Jeremy White, et al.
Journal of Medical Economics|April 9, 2015
Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in NorwayPernilla Huetson, James L Palmer, Andrée Levorsen, et al.
Journal of Medical Economics|May 14, 2011
Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UKAmélie Beaudet, James L Palmer, Louise Timlin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 1, 2010
Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South KoreaKyoung Hee Lee, Se Jin Seo, Jayne Smith-Palmer, et al.
Journal of Medical Economics|January 29, 2015
Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United StatesVolker Foos, Nebibe Varol, Bradley H Curtis, et al.
Current Medical Research and Opinion|April 11, 2008
Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE studyJames L Palmer, Gordon Goodall, Steffen Nielsen, et al.
Journal of Medical Economics|May 20, 2009
Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi ArabiaMohammed Ali, Jeremy White, Chen-Hui Lee, et al.
Pageof 2